Alnylam Pharmaceuticals
ALNY
390 hedge funds and large institutions have $15.4B invested in Alnylam Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 149 increasing their positions, 116 reducing their positions, and 36 closing their positions.
54% more call options, than puts
Call options by funds: $83.9M | Put options by funds: $54.4M
53% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 36
28% more repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 116
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
10% more capital invested
Capital invested by funds: $14B → $15.4B (+$1.39B)
4% more funds holding
Funds holding: 374 → 390 (+16)
0.55% more ownership
Funds ownership: 92.99% → 93.54% (+0.55%)
Top Buyers
Top Sellers
ALNY Hedge Fund Activity: Q1 2021 in Review
390 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2021, worth a combined $15.4B — up 9.9% from $14B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new ALNY positions and 36 closed out — a net gain of 19 holders — while 149 added to existing stakes and 116 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $219M. The largest seller was Wellington Management Group, cutting an estimated $137M.
- 390 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2021, up from 374 in Q4 2020.
- Funds reported $15.4B of Alnylam Pharmaceuticals stock for Q1 2021, up 9.9% quarter-over-quarter.
- 55 funds opened new Alnylam Pharmaceuticals positions in Q1 2021 and 36 closed out, a net change of +19 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $219M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2021 was Wellington Management Group, an estimated $137M sold.
Based on aggregated 13F filings for Q1 2021.